GCM
MRVI icon

Gladius Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Gladius Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,159
Closed -$53.4K – 346
2024
Q1 		$53.4K Buy
6,159
+1,554
+34% +$10.5K 0.02% 173
2023
Q4 		$30.2K Buy
+4,605
New +$29.8K ﹤0.01% 284
2023
Q1 		– Sell
-2,608
Closed -$37.3K – 413
2022
Q4 		$37.3K Buy
+2,608
New +$41.1K ﹤0.01% 243

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Gladius Capital Management's MRVI Position: Q2 2024 in Review

Gladius Capital Management sold out of Maravai LifeSciences (MRVI) in Q2 2024, closing a stake of 6,159 shares — an estimated $53.4K sold.

Gladius Capital Management first reported a position in MRVI in Q4 2022 and held it in 3 quarters. The position peaked at $53.4K in Q1 2024. 206 funds tracked by Wall St. Rank hold MRVI as of Q2 2024.

  • Gladius Capital Management reported no remaining Maravai LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Gladius Capital Management sold 6,159 Maravai LifeSciences shares in Q2 2024, an estimated $53.4K.
  • Gladius Capital Management first reported a position in Maravai LifeSciences in Q4 2022 and held it in 3 quarters.
  • Gladius Capital Management's Maravai LifeSciences position peaked at $53.4K in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2024.

Based on Gladius Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.